SBFC Farmácia Clínica cheat sheet

Pharmaceutical care is the responsible provision of drug therapy to achieve definite outcomes that improve a patient's quality of life; its core elements are assessment of need, identification of problems, and follow-up.

The pharmaceutical care process has three steps: pharmacotherapy workup (assessment), care plan (goals, interventions, monitoring), and follow-up evaluation.

The SOAP note structure organizes documentation into Subjective, Objective, Assessment, and Plan; the Assessment section must state the drug therapy problem, not the medical diagnosis alone.

Seven categories of drug therapy problems: unnecessary therapy, need for additional therapy, ineffective drug, dose too low, adverse drug reaction, dose too high, and nonadherence.

Pharmaceutical care indicators: identification of drug-related problems, resolution rate, adherence, and clinical outcome measures such as blood pressure or HbA1c control.

Pharmacist prescribing and therapeutic substitution require institutional protocols; in Brazil, the pharmacist may perform clinical services such as anamnesis, drug therapy review, and non-prescription dispensing under professional regulation.

The Cipolle-Strand-Morley framework classifies each drug therapy problem as indication, effectiveness, safety, or adherence related, and links each to a specific intervention and monitoring parameter.

Medication reconciliation compares the pre-admission medication list with prescribed orders at admission, transfer, and discharge; discrepancies are documented and resolved with the prescriber.

Hypertension first-line classes: thiazide-type diuretics, ACE inhibitors, angiotensin receptor blockers, and dihydropyridine calcium channel blockers; beta-blockers are first-line when a compelling indication exists (post-MI, heart failure, angina).

Heart failure with reduced ejection fraction quadruple therapy: ARNI or ACE inhibitor/ARB, evidence-based beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor, titrated to target doses.

Statin intensity: high intensity lowers LDL-C by at least 50 percent (atorvastatin 40-80 mg, rosuvastatin 20-40 mg); moderate intensity lowers LDL-C by 30 to 49 percent.

Metformin is first-line for type 2 diabetes unless contraindicated; it is withheld when eGFR falls below 30 mL/min/1.73 m2 and requires dose review at eGFR 30 to 45.

SGLT2 inhibitors reduce heart failure hospitalization and slow CKD progression independent of glucose lowering; euglycemic diabetic ketoacidosis is a recognized adverse effect.

Warfarin monitoring uses INR with target 2.0 to 3.0 for most indications and 2.5 to 3.5 for mechanical mitral valves; DOACs require dose adjustment by renal function, age, and weight.

Anticoagulation in atrial fibrillation uses CHA2DS2-VASc for stroke risk and HAS-BLED for bleeding risk; a high HAS-BLED score prompts correction of modifiable factors, not automatic withholding of anticoagulation.

Acute coronary syndrome: dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) plus parenteral anticoagulation, with high-intensity statin started early.

Empiric therapy is selected by likely pathogen, site of infection, and local resistance patterns; de-escalation to narrower therapy follows culture and susceptibility results.

Beta-lactams are time-dependent killers (target free drug above MIC for 40 to 70 percent of the dosing interval); aminoglycosides are concentration-dependent (target peak-to-MIC ratio and AUC).

Vancomycin AUC-guided dosing targets AUC24/MIC of 400 to 600 for serious MRSA infections; trough-only monitoring is an alternative when AUC is not feasible.

Aminoglycoside monitoring: peak concentration for efficacy and trough for toxicity; extended-interval dosing uses a single high dose and a random or trough level.

Antimicrobial stewardship core interventions: prospective audit and feedback, prior authorization, formulary restriction, de-escalation, dose optimization, and duration limits.

Carbapenem-sparing strategies for ESBL-producing Enterobacterales include ertapenem, piperacillin-tazobactam (selected cases), and non-beta-lactam options guided by susceptibility.

Tuberculosis treatment uses a rifampicin, isoniazid, pyrazinamide, and ethambutol intensive phase followed by a continuation phase; isoniazid requires pyridoxine supplementation to prevent neuropathy.

Antiretroviral first-line regimens combine two nucleoside reverse transcriptase inhibitors with an integrase inhibitor; drug interactions with rifampicin and with polyvalent cations must be screened.

Depression first-line agents: SSRIs, SNRIs, mirtazapine, and bupropion; onset of full effect takes 4 to 8 weeks, and treatment continues for at least 6 to 12 months after remission.

Serotonin syndrome presents with mental status change, autonomic hyperactivity, and neuromuscular abnormalities (clonus, hyperreflexia); it is treated by stopping serotonergic drugs and supportive care.

Bipolar disorder mania uses lithium, valproate, or atypical antipsychotics; antidepressant monotherapy risks inducing a manic switch.

Lithium has a narrow therapeutic index (0.6 to 1.2 mEq/L); toxicity is precipitated by dehydration, NSAIDs, thiazides, and ACE inhibitors, and requires level monitoring.

Epilepsy drug selection depends on seizure type: valproate is broad-spectrum but teratogenic; carbamazepine and oxcarbazepine worsen absence and myoclonic seizures.

Parkinson disease: levodopa-carbidopa is the most effective motor therapy; dopamine agonists are preferred in younger patients to delay motor complications.

Antipsychotic adverse effects: extrapyramidal symptoms with high-potency first-generation agents, metabolic syndrome with second-generation agents, and QT prolongation with several agents.

Opioid use disorder maintenance uses buprenorphine or methadone; naloxone reverses acute opioid overdose but has a shorter duration than many opioids, requiring observation.

Asthma stepwise therapy: as-needed short-acting beta-agonist alone is no longer preferred; low-dose inhaled corticosteroid-formoterol is used as reliever and controller in mild asthma.

COPD maintenance uses long-acting bronchodilators (LAMA, LABA); inhaled corticosteroids are added for frequent exacerbations or eosinophilic inflammation.

Gastroesophageal reflux disease: proton pump inhibitors are taken 30 to 60 minutes before a meal; a trial of 8 weeks is standard, and step-down is considered after control.

Helicobacter pylori eradication uses a proton pump inhibitor plus two or three antibiotics (for example amoxicillin, clarithromycin, or metronidazole) for 10 to 14 days, with eradication confirmed by urea breath test.

Chronic kidney disease management targets blood pressure below 130/80 mmHg, uses ACE inhibitors or ARBs for albuminuria, and adds SGLT2 inhibitors for kidney and cardiovascular protection.

Hyperkalemia treatment: calcium gluconate stabilizes the myocardium, insulin with glucose and beta-agonists shift potassium intracellularly, and diuretics or binders remove potassium.

Acute kidney injury requires review of nephrotoxic drugs (NSAIDs, aminoglycosides, contrast media), dose adjustment for renal function, and assessment of volume status.

Inflammatory bowel disease: aminosalicylates for mild ulcerative colitis, corticosteroids for induction, and thiopurines or biologics for maintenance.

Chemotherapy toxicity timing: neutropenia nadir occurs about 7 to 14 days after administration; emetogenic risk guides prophylaxis with 5-HT3 antagonist, dexamethasone, and NK1 antagonist for highly emetogenic regimens.

Tumor lysis syndrome prevention uses allopurinol for low risk and rasburicase for high risk, with hydration and monitoring of potassium, phosphate, calcium, and uric acid.

Methotrexate toxicity is managed with leucovorin rescue; glucarpidase is used for high-dose methotrexate with delayed clearance and renal impairment.

Anthracyclines cause cumulative dose-dependent cardiotoxicity; doxorubicin risk rises above approximately 550 mg/m2, and dexrazoxane is a cardioprotectant.

Immunosuppressants: tacrolimus and cyclosporine are calcineurin inhibitors with narrow therapeutic indices requiring trough monitoring; mycophenolate is teratogenic and requires contraception.

Tacrolimus and cyclosporine are CYP3A4 substrates; azole antifungals and macrolides raise their levels, while rifampicin lowers them.

Heparin-induced thrombocytopenia is immune-mediated, causes thrombosis rather than bleeding, and requires stopping heparin and starting a non-heparin anticoagulant such as argatroban.

Febrile neutropenia requires prompt empiric broad-spectrum antibiotics, typically an antipseudomonal beta-lactam, within one hour of presentation.

Clearance equals dose rate divided by steady-state concentration; at steady state, dosing rate equals clearance multiplied by average concentration.

Half-life equals 0.693 times volume of distribution divided by clearance; it takes about 4 to 5 half-lives to reach steady state.

Loading dose equals target concentration times volume of distribution divided by bioavailability; maintenance dose equals clearance times target concentration times dosing interval divided by bioavailability.

Therapeutic drug monitoring is indicated for drugs with narrow therapeutic index, established concentration-response relationships, and unpredictable kinetics (digoxin, lithium, vancomycin, aminoglycosides, phenytoin, tacrolimus).

Phenytoin follows Michaelis-Menten (saturable) kinetics; small dose increases can produce disproportionate rises in serum concentration.

Bioavailability is the fraction of an oral dose reaching systemic circulation; first-pass hepatic metabolism reduces it and raises the oral-to-IV dose ratio.

Renal dose adjustment uses Cockcroft-Gault creatinine clearance for most drugs; the CKD-EPI equation is used for kidney staging rather than drug dosing.

Pharmacodynamic interactions may be additive, synergistic, or antagonistic; the therapeutic index describes the margin between effective and toxic concentrations.

CYP2D6 poor metabolizers have reduced conversion of codeine to morphine and reduced analgesia; ultrarapid metabolizers risk morphine toxicity, so codeine is avoided in both extremes.

CYP2C19 loss-of-function alleles reduce clopidogrel activation; alternative P2Y12 inhibitors such as prasugrel or ticagrelor are preferred after acute coronary syndrome.

HLA-B57:01 screening prevents abacavir hypersensitivity; HLA-B15:02 screening prevents carbamazepine-induced Stevens-Johnson syndrome in at-risk Asian populations.

TPMT and NUDT15 deficiency increases thiopurine (azathioprine, mercaptopurine) toxicity; testing guides dose reduction or alternative therapy.

G6PD deficiency contraindicates primaquine, dapsone, nitrofurantoin, and rasburicase because of hemolysis risk.

CYP2C9 and VKORC1 variants influence warfarin dose requirements; genotype-guided dosing may reduce bleeding and is used in some protocols.

DPYD deficiency increases fluoropyrimidine toxicity; DPYD genotyping before 5-fluorouracil or capecitabine reduces severe toxicity.

Precision medicine selects therapy by biomarkers such as HER2 amplification, EGFR mutations, and KRAS status, which determine response to targeted agents.

An adverse drug reaction is any noxious, unintended response to a drug at normal doses; causality assessment uses the WHO-UMC or Naranjo scale.

Serious adverse reactions are those causing death, hospitalization, disability, congenital anomaly, or life-threatening events, and must be reported to the regulatory authority.

Pharmacovigilance activities include spontaneous reporting, signal detection, periodic safety update reports, and risk management plans.

CYP3A4 inhibitors include ketoconazole, clarithromycin, ritonavir, and grapefruit; inducers include rifampicin, carbamazepine, phenytoin, and St John's wort.

High-alert medications (insulin, anticoagulants, concentrated electrolytes, chemotherapy, opioids) require independent double-checks and standardized concentrations.

Look-alike, sound-alike drug names (for example, hydroxyzine and hydralazine) are a leading source of dispensing errors; tall-man lettering and barcode verification reduce risk.

Absorption interactions: tetracyclines and fluoroquinolones chelate with calcium, magnesium, iron, and aluminum; doses must be separated by at least two hours.

Pharmacodynamic interactions include additive QT prolongation and additive bleeding risk with anticoagulants plus antiplatelet agents or NSAIDs.

Prescription-only medicines require a valid prescription; special control medicines use specific notification forms (receita de controle especial) with retention and validity rules.

Antimicrobials in Brazil require a two-copy prescription retained by the pharmacy, with defined validity, under rules restricting dispensing without a prescription.

The Brazilian Pharmacist's Code of Ethics requires confidentiality, informed consent, and refusal to participate in procedures contrary to professional standards.

Pharmacists may perform clinical services such as anamnesis, medication review, and administration of injectable and immunizing agents under professional regulation.

Professional liability follows the principle of personal responsibility; the pharmacist answers for acts performed and must document interventions in the patient record.

Dispensing of generic medicines requires bioequivalence approval by the regulatory authority; substitution of a prescribed brand requires prescriber authorization unless legally permitted.

Pharmacovigilance reporting in Brazil uses the national notification system, and pharmacies must retain records enabling product traceability and recall.

Controlled substance records must be kept for the period defined by regulation and made available for inspection; deviations trigger administrative and criminal liability.

Pharmaceutical care is the responsible provision of drug therapy to achieve definite outcomes that improve a patient's quality of life; its core elements are assessment of need, identification of problems, and follow-up.

The pharmaceutical care process has three steps: pharmacotherapy workup (assessment), care plan (goals, interventions, monitoring), and follow-up evaluation.

The SOAP note structure organizes documentation into Subjective, Objective, Assessment, and Plan; the Assessment section must state the drug therapy problem, not the medical diagnosis alone.

Seven categories of drug therapy problems: unnecessary therapy, need for additional therapy, ineffective drug, dose too low, adverse drug reaction, dose too high, and nonadherence.

Pharmaceutical care indicators: identification of drug-related problems, resolution rate, adherence, and clinical outcome measures such as blood pressure or HbA1c control.

Pharmacist prescribing and therapeutic substitution require institutional protocols; in Brazil, the pharmacist may perform clinical services such as anamnesis, drug therapy review, and non-prescription dispensing under professional regulation.

The Cipolle-Strand-Morley framework classifies each drug therapy problem as indication, effectiveness, safety, or adherence related, and links each to a specific intervention and monitoring parameter.

Medication reconciliation compares the pre-admission medication list with prescribed orders at admission, transfer, and discharge; discrepancies are documented and resolved with the prescriber.

Hypertension first-line classes: thiazide-type diuretics, ACE inhibitors, angiotensin receptor blockers, and dihydropyridine calcium channel blockers; beta-blockers are first-line when a compelling indication exists (post-MI, heart failure, angina).

Heart failure with reduced ejection fraction quadruple therapy: ARNI or ACE inhibitor/ARB, evidence-based beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor, titrated to target doses.

Statin intensity: high intensity lowers LDL-C by at least 50 percent (atorvastatin 40-80 mg, rosuvastatin 20-40 mg); moderate intensity lowers LDL-C by 30 to 49 percent.

Metformin is first-line for type 2 diabetes unless contraindicated; it is withheld when eGFR falls below 30 mL/min/1.73 m2 and requires dose review at eGFR 30 to 45.

SGLT2 inhibitors reduce heart failure hospitalization and slow CKD progression independent of glucose lowering; euglycemic diabetic ketoacidosis is a recognized adverse effect.

Warfarin monitoring uses INR with target 2.0 to 3.0 for most indications and 2.5 to 3.5 for mechanical mitral valves; DOACs require dose adjustment by renal function, age, and weight.

Anticoagulation in atrial fibrillation uses CHA2DS2-VASc for stroke risk and HAS-BLED for bleeding risk; a high HAS-BLED score prompts correction of modifiable factors, not automatic withholding of anticoagulation.

Acute coronary syndrome: dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) plus parenteral anticoagulation, with high-intensity statin started early.

Empiric therapy is selected by likely pathogen, site of infection, and local resistance patterns; de-escalation to narrower therapy follows culture and susceptibility results.

Beta-lactams are time-dependent killers (target free drug above MIC for 40 to 70 percent of the dosing interval); aminoglycosides are concentration-dependent (target peak-to-MIC ratio and AUC).

Vancomycin AUC-guided dosing targets AUC24/MIC of 400 to 600 for serious MRSA infections; trough-only monitoring is an alternative when AUC is not feasible.

Aminoglycoside monitoring: peak concentration for efficacy and trough for toxicity; extended-interval dosing uses a single high dose and a random or trough level.

Antimicrobial stewardship core interventions: prospective audit and feedback, prior authorization, formulary restriction, de-escalation, dose optimization, and duration limits.

Carbapenem-sparing strategies for ESBL-producing Enterobacterales include ertapenem, piperacillin-tazobactam (selected cases), and non-beta-lactam options guided by susceptibility.

Tuberculosis treatment uses a rifampicin, isoniazid, pyrazinamide, and ethambutol intensive phase followed by a continuation phase; isoniazid requires pyridoxine supplementation to prevent neuropathy.

Antiretroviral first-line regimens combine two nucleoside reverse transcriptase inhibitors with an integrase inhibitor; drug interactions with rifampicin and with polyvalent cations must be screened.

Depression first-line agents: SSRIs, SNRIs, mirtazapine, and bupropion; onset of full effect takes 4 to 8 weeks, and treatment continues for at least 6 to 12 months after remission.

Serotonin syndrome presents with mental status change, autonomic hyperactivity, and neuromuscular abnormalities (clonus, hyperreflexia); it is treated by stopping serotonergic drugs and supportive care.

Bipolar disorder mania uses lithium, valproate, or atypical antipsychotics; antidepressant monotherapy risks inducing a manic switch.

Lithium has a narrow therapeutic index (0.6 to 1.2 mEq/L); toxicity is precipitated by dehydration, NSAIDs, thiazides, and ACE inhibitors, and requires level monitoring.

Epilepsy drug selection depends on seizure type: valproate is broad-spectrum but teratogenic; carbamazepine and oxcarbazepine worsen absence and myoclonic seizures.

Parkinson disease: levodopa-carbidopa is the most effective motor therapy; dopamine agonists are preferred in younger patients to delay motor complications.

Antipsychotic adverse effects: extrapyramidal symptoms with high-potency first-generation agents, metabolic syndrome with second-generation agents, and QT prolongation with several agents.

Opioid use disorder maintenance uses buprenorphine or methadone; naloxone reverses acute opioid overdose but has a shorter duration than many opioids, requiring observation.

Asthma stepwise therapy: as-needed short-acting beta-agonist alone is no longer preferred; low-dose inhaled corticosteroid-formoterol is used as reliever and controller in mild asthma.

COPD maintenance uses long-acting bronchodilators (LAMA, LABA); inhaled corticosteroids are added for frequent exacerbations or eosinophilic inflammation.

Gastroesophageal reflux disease: proton pump inhibitors are taken 30 to 60 minutes before a meal; a trial of 8 weeks is standard, and step-down is considered after control.

Helicobacter pylori eradication uses a proton pump inhibitor plus two or three antibiotics (for example amoxicillin, clarithromycin, or metronidazole) for 10 to 14 days, with eradication confirmed by urea breath test.

Chronic kidney disease management targets blood pressure below 130/80 mmHg, uses ACE inhibitors or ARBs for albuminuria, and adds SGLT2 inhibitors for kidney and cardiovascular protection.

Hyperkalemia treatment: calcium gluconate stabilizes the myocardium, insulin with glucose and beta-agonists shift potassium intracellularly, and diuretics or binders remove potassium.

Acute kidney injury requires review of nephrotoxic drugs (NSAIDs, aminoglycosides, contrast media), dose adjustment for renal function, and assessment of volume status.

Inflammatory bowel disease: aminosalicylates for mild ulcerative colitis, corticosteroids for induction, and thiopurines or biologics for maintenance.

Chemotherapy toxicity timing: neutropenia nadir occurs about 7 to 14 days after administration; emetogenic risk guides prophylaxis with 5-HT3 antagonist, dexamethasone, and NK1 antagonist for highly emetogenic regimens.

Tumor lysis syndrome prevention uses allopurinol for low risk and rasburicase for high risk, with hydration and monitoring of potassium, phosphate, calcium, and uric acid.

Methotrexate toxicity is managed with leucovorin rescue; glucarpidase is used for high-dose methotrexate with delayed clearance and renal impairment.

Anthracyclines cause cumulative dose-dependent cardiotoxicity; doxorubicin risk rises above approximately 550 mg/m2, and dexrazoxane is a cardioprotectant.

Immunosuppressants: tacrolimus and cyclosporine are calcineurin inhibitors with narrow therapeutic indices requiring trough monitoring; mycophenolate is teratogenic and requires contraception.

Tacrolimus and cyclosporine are CYP3A4 substrates; azole antifungals and macrolides raise their levels, while rifampicin lowers them.

Heparin-induced thrombocytopenia is immune-mediated, causes thrombosis rather than bleeding, and requires stopping heparin and starting a non-heparin anticoagulant such as argatroban.

Febrile neutropenia requires prompt empiric broad-spectrum antibiotics, typically an antipseudomonal beta-lactam, within one hour of presentation.

Clearance equals dose rate divided by steady-state concentration; at steady state, dosing rate equals clearance multiplied by average concentration.

Half-life equals 0.693 times volume of distribution divided by clearance; it takes about 4 to 5 half-lives to reach steady state.

Loading dose equals target concentration times volume of distribution divided by bioavailability; maintenance dose equals clearance times target concentration times dosing interval divided by bioavailability.

Therapeutic drug monitoring is indicated for drugs with narrow therapeutic index, established concentration-response relationships, and unpredictable kinetics (digoxin, lithium, vancomycin, aminoglycosides, phenytoin, tacrolimus).

Phenytoin follows Michaelis-Menten (saturable) kinetics; small dose increases can produce disproportionate rises in serum concentration.

Bioavailability is the fraction of an oral dose reaching systemic circulation; first-pass hepatic metabolism reduces it and raises the oral-to-IV dose ratio.

Renal dose adjustment uses Cockcroft-Gault creatinine clearance for most drugs; the CKD-EPI equation is used for kidney staging rather than drug dosing.

Pharmacodynamic interactions may be additive, synergistic, or antagonistic; the therapeutic index describes the margin between effective and toxic concentrations.

CYP2D6 poor metabolizers have reduced conversion of codeine to morphine and reduced analgesia; ultrarapid metabolizers risk morphine toxicity, so codeine is avoided in both extremes.

CYP2C19 loss-of-function alleles reduce clopidogrel activation; alternative P2Y12 inhibitors such as prasugrel or ticagrelor are preferred after acute coronary syndrome.

HLA-B57:01 screening prevents abacavir hypersensitivity; HLA-B15:02 screening prevents carbamazepine-induced Stevens-Johnson syndrome in at-risk Asian populations.

TPMT and NUDT15 deficiency increases thiopurine (azathioprine, mercaptopurine) toxicity; testing guides dose reduction or alternative therapy.

G6PD deficiency contraindicates primaquine, dapsone, nitrofurantoin, and rasburicase because of hemolysis risk.

CYP2C9 and VKORC1 variants influence warfarin dose requirements; genotype-guided dosing may reduce bleeding and is used in some protocols.

DPYD deficiency increases fluoropyrimidine toxicity; DPYD genotyping before 5-fluorouracil or capecitabine reduces severe toxicity.

Precision medicine selects therapy by biomarkers such as HER2 amplification, EGFR mutations, and KRAS status, which determine response to targeted agents.

An adverse drug reaction is any noxious, unintended response to a drug at normal doses; causality assessment uses the WHO-UMC or Naranjo scale.

Serious adverse reactions are those causing death, hospitalization, disability, congenital anomaly, or life-threatening events, and must be reported to the regulatory authority.

Pharmacovigilance activities include spontaneous reporting, signal detection, periodic safety update reports, and risk management plans.

CYP3A4 inhibitors include ketoconazole, clarithromycin, ritonavir, and grapefruit; inducers include rifampicin, carbamazepine, phenytoin, and St John's wort.

High-alert medications (insulin, anticoagulants, concentrated electrolytes, chemotherapy, opioids) require independent double-checks and standardized concentrations.

Look-alike, sound-alike drug names (for example, hydroxyzine and hydralazine) are a leading source of dispensing errors; tall-man lettering and barcode verification reduce risk.

Absorption interactions: tetracyclines and fluoroquinolones chelate with calcium, magnesium, iron, and aluminum; doses must be separated by at least two hours.

Pharmacodynamic interactions include additive QT prolongation and additive bleeding risk with anticoagulants plus antiplatelet agents or NSAIDs.

Prescription-only medicines require a valid prescription; special control medicines use specific notification forms (receita de controle especial) with retention and validity rules.

Antimicrobials in Brazil require a two-copy prescription retained by the pharmacy, with defined validity, under rules restricting dispensing without a prescription.

The Brazilian Pharmacist's Code of Ethics requires confidentiality, informed consent, and refusal to participate in procedures contrary to professional standards.

Pharmacists may perform clinical services such as anamnesis, medication review, and administration of injectable and immunizing agents under professional regulation.

Professional liability follows the principle of personal responsibility; the pharmacist answers for acts performed and must document interventions in the patient record.

Dispensing of generic medicines requires bioequivalence approval by the regulatory authority; substitution of a prescribed brand requires prescriber authorization unless legally permitted.

Pharmacovigilance reporting in Brazil uses the national notification system, and pharmacies must retain records enabling product traceability and recall.

Controlled substance records must be kept for the period defined by regulation and made available for inspection; deviations trigger administrative and criminal liability.

Pharmaceutical care is the responsible provision of drug therapy to achieve definite outcomes that improve a patient's quality of life; its core elements are assessment of need, identification of problems, and follow-up.

The pharmaceutical care process has three steps: pharmacotherapy workup (assessment), care plan (goals, interventions, monitoring), and follow-up evaluation.

The SOAP note structure organizes documentation into Subjective, Objective, Assessment, and Plan; the Assessment section must state the drug therapy problem, not the medical diagnosis alone.

Seven categories of drug therapy problems: unnecessary therapy, need for additional therapy, ineffective drug, dose too low, adverse drug reaction, dose too high, and nonadherence.

Pharmaceutical care indicators: identification of drug-related problems, resolution rate, adherence, and clinical outcome measures such as blood pressure or HbA1c control.

Pharmacist prescribing and therapeutic substitution require institutional protocols; in Brazil, the pharmacist may perform clinical services such as anamnesis, drug therapy review, and non-prescription dispensing under professional regulation.

The Cipolle-Strand-Morley framework classifies each drug therapy problem as indication, effectiveness, safety, or adherence related, and links each to a specific intervention and monitoring parameter.

Medication reconciliation compares the pre-admission medication list with prescribed orders at admission, transfer, and discharge; discrepancies are documented and resolved with the prescriber.

Hypertension first-line classes: thiazide-type diuretics, ACE inhibitors, angiotensin receptor blockers, and dihydropyridine calcium channel blockers; beta-blockers are first-line when a compelling indication exists (post-MI, heart failure, angina).

Heart failure with reduced ejection fraction quadruple therapy: ARNI or ACE inhibitor/ARB, evidence-based beta-blocker, mineralocorticoid receptor antagonist, and SGLT2 inhibitor, titrated to target doses.

Statin intensity: high intensity lowers LDL-C by at least 50 percent (atorvastatin 40-80 mg, rosuvastatin 20-40 mg); moderate intensity lowers LDL-C by 30 to 49 percent.

Metformin is first-line for type 2 diabetes unless contraindicated; it is withheld when eGFR falls below 30 mL/min/1.73 m2 and requires dose review at eGFR 30 to 45.

SGLT2 inhibitors reduce heart failure hospitalization and slow CKD progression independent of glucose lowering; euglycemic diabetic ketoacidosis is a recognized adverse effect.

Warfarin monitoring uses INR with target 2.0 to 3.0 for most indications and 2.5 to 3.5 for mechanical mitral valves; DOACs require dose adjustment by renal function, age, and weight.

Anticoagulation in atrial fibrillation uses CHA2DS2-VASc for stroke risk and HAS-BLED for bleeding risk; a high HAS-BLED score prompts correction of modifiable factors, not automatic withholding of anticoagulation.

Acute coronary syndrome: dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) plus parenteral anticoagulation, with high-intensity statin started early.

Empiric therapy is selected by likely pathogen, site of infection, and local resistance patterns; de-escalation to narrower therapy follows culture and susceptibility results.

Beta-lactams are time-dependent killers (target free drug above MIC for 40 to 70 percent of the dosing interval); aminoglycosides are concentration-dependent (target peak-to-MIC ratio and AUC).

Vancomycin AUC-guided dosing targets AUC24/MIC of 400 to 600 for serious MRSA infections; trough-only monitoring is an alternative when AUC is not feasible.

Aminoglycoside monitoring: peak concentration for efficacy and trough for toxicity; extended-interval dosing uses a single high dose and a random or trough level.

Antimicrobial stewardship core interventions: prospective audit and feedback, prior authorization, formulary restriction, de-escalation, dose optimization, and duration limits.

Carbapenem-sparing strategies for ESBL-producing Enterobacterales include ertapenem, piperacillin-tazobactam (selected cases), and non-beta-lactam options guided by susceptibility.

Tuberculosis treatment uses a rifampicin, isoniazid, pyrazinamide, and ethambutol intensive phase followed by a continuation phase; isoniazid requires pyridoxine supplementation to prevent neuropathy.

Antiretroviral first-line regimens combine two nucleoside reverse transcriptase inhibitors with an integrase inhibitor; drug interactions with rifampicin and with polyvalent cations must be screened.

Depression first-line agents: SSRIs, SNRIs, mirtazapine, and bupropion; onset of full effect takes 4 to 8 weeks, and treatment continues for at least 6 to 12 months after remission.

Serotonin syndrome presents with mental status change, autonomic hyperactivity, and neuromuscular abnormalities (clonus, hyperreflexia); it is treated by stopping serotonergic drugs and supportive care.

Bipolar disorder mania uses lithium, valproate, or atypical antipsychotics; antidepressant monotherapy risks inducing a manic switch.

Lithium has a narrow therapeutic index (0.6 to 1.2 mEq/L); toxicity is precipitated by dehydration, NSAIDs, thiazides, and ACE inhibitors, and requires level monitoring.

Epilepsy drug selection depends on seizure type: valproate is broad-spectrum but teratogenic; carbamazepine and oxcarbazepine worsen absence and myoclonic seizures.

Parkinson disease: levodopa-carbidopa is the most effective motor therapy; dopamine agonists are preferred in younger patients to delay motor complications.

Antipsychotic adverse effects: extrapyramidal symptoms with high-potency first-generation agents, metabolic syndrome with second-generation agents, and QT prolongation with several agents.

Opioid use disorder maintenance uses buprenorphine or methadone; naloxone reverses acute opioid overdose but has a shorter duration than many opioids, requiring observation.

Asthma stepwise therapy: as-needed short-acting beta-agonist alone is no longer preferred; low-dose inhaled corticosteroid-formoterol is used as reliever and controller in mild asthma.

COPD maintenance uses long-acting bronchodilators (LAMA, LABA); inhaled corticosteroids are added for frequent exacerbations or eosinophilic inflammation.

Gastroesophageal reflux disease: proton pump inhibitors are taken 30 to 60 minutes before a meal; a trial of 8 weeks is standard, and step-down is considered after control.

Helicobacter pylori eradication uses a proton pump inhibitor plus two or three antibiotics (for example amoxicillin, clarithromycin, or metronidazole) for 10 to 14 days, with eradication confirmed by urea breath test.

Chronic kidney disease management targets blood pressure below 130/80 mmHg, uses ACE inhibitors or ARBs for albuminuria, and adds SGLT2 inhibitors for kidney and cardiovascular protection.

Hyperkalemia treatment: calcium gluconate stabilizes the myocardium, insulin with glucose and beta-agonists shift potassium intracellularly, and diuretics or binders remove potassium.

Acute kidney injury requires review of nephrotoxic drugs (NSAIDs, aminoglycosides, contrast media), dose adjustment for renal function, and assessment of volume status.

Inflammatory bowel disease: aminosalicylates for mild ulcerative colitis, corticosteroids for induction, and thiopurines or biologics for maintenance.

Chemotherapy toxicity timing: neutropenia nadir occurs about 7 to 14 days after administration; emetogenic risk guides prophylaxis with 5-HT3 antagonist, dexamethasone, and NK1 antagonist for highly emetogenic regimens.

Tumor lysis syndrome prevention uses allopurinol for low risk and rasburicase for high risk, with hydration and monitoring of potassium, phosphate, calcium, and uric acid.

Methotrexate toxicity is managed with leucovorin rescue; glucarpidase is used for high-dose methotrexate with delayed clearance and renal impairment.

Anthracyclines cause cumulative dose-dependent cardiotoxicity; doxorubicin risk rises above approximately 550 mg/m2, and dexrazoxane is a cardioprotectant.

Immunosuppressants: tacrolimus and cyclosporine are calcineurin inhibitors with narrow therapeutic indices requiring trough monitoring; mycophenolate is teratogenic and requires contraception.

Tacrolimus and cyclosporine are CYP3A4 substrates; azole antifungals and macrolides raise their levels, while rifampicin lowers them.

Heparin-induced thrombocytopenia is immune-mediated, causes thrombosis rather than bleeding, and requires stopping heparin and starting a non-heparin anticoagulant such as argatroban.

Febrile neutropenia requires prompt empiric broad-spectrum antibiotics, typically an antipseudomonal beta-lactam, within one hour of presentation.

Clearance equals dose rate divided by steady-state concentration; at steady state, dosing rate equals clearance multiplied by average concentration.

Half-life equals 0.693 times volume of distribution divided by clearance; it takes about 4 to 5 half-lives to reach steady state.

Loading dose equals target concentration times volume of distribution divided by bioavailability; maintenance dose equals clearance times target concentration times dosing interval divided by bioavailability.

Therapeutic drug monitoring is indicated for drugs with narrow therapeutic index, established concentration-response relationships, and unpredictable kinetics (digoxin, lithium, vancomycin, aminoglycosides, phenytoin, tacrolimus).

Phenytoin follows Michaelis-Menten (saturable) kinetics; small dose increases can produce disproportionate rises in serum concentration.

Bioavailability is the fraction of an oral dose reaching systemic circulation; first-pass hepatic metabolism reduces it and raises the oral-to-IV dose ratio.

Renal dose adjustment uses Cockcroft-Gault creatinine clearance for most drugs; the CKD-EPI equation is used for kidney staging rather than drug dosing.

Pharmacodynamic interactions may be additive, synergistic, or antagonistic; the therapeutic index describes the margin between effective and toxic concentrations.

CYP2D6 poor metabolizers have reduced conversion of codeine to morphine and reduced analgesia; ultrarapid metabolizers risk morphine toxicity, so codeine is avoided in both extremes.

CYP2C19 loss-of-function alleles reduce clopidogrel activation; alternative P2Y12 inhibitors such as prasugrel or ticagrelor are preferred after acute coronary syndrome.

HLA-B57:01 screening prevents abacavir hypersensitivity; HLA-B15:02 screening prevents carbamazepine-induced Stevens-Johnson syndrome in at-risk Asian populations.

TPMT and NUDT15 deficiency increases thiopurine (azathioprine, mercaptopurine) toxicity; testing guides dose reduction or alternative therapy.

G6PD deficiency contraindicates primaquine, dapsone, nitrofurantoin, and rasburicase because of hemolysis risk.

CYP2C9 and VKORC1 variants influence warfarin dose requirements; genotype-guided dosing may reduce bleeding and is used in some protocols.

DPYD deficiency increases fluoropyrimidine toxicity; DPYD genotyping before 5-fluorouracil or capecitabine reduces severe toxicity.

Precision medicine selects therapy by biomarkers such as HER2 amplification, EGFR mutations, and KRAS status, which determine response to targeted agents.

An adverse drug reaction is any noxious, unintended response to a drug at normal doses; causality assessment uses the WHO-UMC or Naranjo scale.

Serious adverse reactions are those causing death, hospitalization, disability, congenital anomaly, or life-threatening events, and must be reported to the regulatory authority.

Pharmacovigilance activities include spontaneous reporting, signal detection, periodic safety update reports, and risk management plans.

CYP3A4 inhibitors include ketoconazole, clarithromycin, ritonavir, and grapefruit; inducers include rifampicin, carbamazepine, phenytoin, and St John's wort.

High-alert medications (insulin, anticoagulants, concentrated electrolytes, chemotherapy, opioids) require independent double-checks and standardized concentrations.

Look-alike, sound-alike drug names (for example, hydroxyzine and hydralazine) are a leading source of dispensing errors; tall-man lettering and barcode verification reduce risk.

Absorption interactions: tetracyclines and fluoroquinolones chelate with calcium, magnesium, iron, and aluminum; doses must be separated by at least two hours.

Pharmacodynamic interactions include additive QT prolongation and additive bleeding risk with anticoagulants plus antiplatelet agents or NSAIDs.

Prescription-only medicines require a valid prescription; special control medicines use specific notification forms (receita de controle especial) with retention and validity rules.

Antimicrobials in Brazil require a two-copy prescription retained by the pharmacy, with defined validity, under rules restricting dispensing without a prescription.

The Brazilian Pharmacist's Code of Ethics requires confidentiality, informed consent, and refusal to participate in procedures contrary to professional standards.

Pharmacists may perform clinical services such as anamnesis, medication review, and administration of injectable and immunizing agents under professional regulation.

Professional liability follows the principle of personal responsibility; the pharmacist answers for acts performed and must document interventions in the patient record.

Dispensing of generic medicines requires bioequivalence approval by the regulatory authority; substitution of a prescribed brand requires prescriber authorization unless legally permitted.

Pharmacovigilance reporting in Brazil uses the national notification system, and pharmacies must retain records enabling product traceability and recall.

Controlled substance records must be kept for the period defined by regulation and made available for inspection; deviations trigger administrative and criminal liability.